MedTrace Logo

Brugada Ablation of VF Substrate Ongoing MultiCenter Registry

NCT04420078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2024-11-21

No results posted yet for this study

Summary

Current treatment of high-risk Brugada Syndrome (BrS) patients (pts) with recurrent VF is limited. Catheter ablation (CA) has been performed for BrS but a large study with long-term outcomes of CA in BrS ablation are lacking.

Conditions

  • Brugada Syndrome

Interventions

PROCEDURE

Catheter Ablation

Ventricular fibrillation substrate

Sponsors & Collaborators

  • University Hospital, Bordeaux

    collaborator OTHER

  • University of Tsukuba

    collaborator OTHER

  • University of London

    collaborator OTHER

  • University of Amsterdam

    collaborator OTHER

  • Ogaki Municipal Hospital

    collaborator UNKNOWN

  • Indiana University

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Zhejiang University

    collaborator OTHER

  • Pacific Rim Electrophysiology Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2022-02-28
Completion
2023-12-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420078 on ClinicalTrials.gov